According to previous studies, camrelizumab-related adverse events primarily manifest as reactive capillary endothelial proliferation, hypothyroidism, hyperthyroidism, alanine aminotransferase increased, and immune-mediated enterocolitis [29, 30]. The gene discussed is GPT; the disease is hypothyroidism.